MCID: PNC094
MIFTS: 27

Pancreatic Cancer 1

Categories: Genetic diseases, Endocrine diseases, Cancer diseases, Rare diseases, Gastrointestinal diseases

Aliases & Classifications for Pancreatic Cancer 1

MalaCards integrated aliases for Pancreatic Cancer 1:

Name: Pancreatic Cancer 1 54 71 29
Pancreatic Cancer, Susceptibility to, 1 13
Pnca1 71

Classifications:



External Ids:

OMIM 54 606856
MedGen 40 C1847351
MeSH 42 D010190

Summaries for Pancreatic Cancer 1

UniProtKB/Swiss-Prot : 71 Pancreatic cancer 1: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.

MalaCards based summary : Pancreatic Cancer 1, also known as pancreatic cancer, susceptibility to, 1, is related to pancreatic cancer susceptibility 1. An important gene associated with Pancreatic Cancer 1 is PALLD (Palladin, Cytoskeletal Associated Protein). The drugs Secretin and Pancrelipase have been mentioned in the context of this disorder. Affiliated tissues include pancreas, lung and t cells.

Description from OMIM: 606856

Related Diseases for Pancreatic Cancer 1

Diseases in the Pancreatic Cancer family:

Pancreatic Cancer 1 Pancreatic Cancer 2
Pancreatic Cancer 3 Pancreatic Cancer 4

Diseases related to Pancreatic Cancer 1 via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 pancreatic cancer susceptibility 1 10.8

Symptoms & Phenotypes for Pancreatic Cancer 1

Clinical features from OMIM:

606856

Drugs & Therapeutics for Pancreatic Cancer 1

Drugs for Pancreatic Cancer 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 536)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Secretin Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1 108153-74-8
2
Pancrelipase Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53608-75-6
3
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
4
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 95058-81-4 60750
5
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 33069-62-4 36314
6
Morphine Approved, Investigational Phase 4 57-27-2 5288826
7
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
8
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
9
Dalteparin Approved Phase 4,Phase 3,Phase 1,Phase 2 9005-49-6
10
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 9005-49-6 772 46507594
11
Etomidate Approved Phase 4 33125-97-2 36339 667484
12
Meperidine Approved Phase 4 57-42-1 4058
13
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
14
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
15
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 2078-54-8 4943
16
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
17
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
18
Tegafur Approved Phase 4,Phase 2,Phase 1 17902-23-7 5386
19
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
20 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
21 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
22 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
24 pancreatin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Adjuvants, Anesthesia Phase 4
26 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Analgesics, Opioid Phase 4,Phase 1
28 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Anesthetics, General Phase 4,Early Phase 1
30 Anesthetics, Intravenous Phase 4,Early Phase 1
31 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
32 Narcotics Phase 4,Phase 1
33 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
35 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
36 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Antimitotic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
40 Antineoplastic Agents, Phytogenic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
41 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43
s 1 (combination) Phase 4,Phase 3,Phase 2,Phase 1
44 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45
Erlotinib Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1 183319-69-9 176871
46 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
47 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
48 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1
49 calcium heparin Phase 4,Phase 2,Phase 3,Phase 1
50 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 1345)

id Name Status NCT ID Phase Drugs
1 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
2 Efficacy of Secretin MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis Unknown status NCT01845467 Phase 4
3 Standard and Immunostimulating Enteral Nutrition in Surgical Patients Completed NCT00576940 Phase 4 Reconvan;Peptisorb
4 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
5 The Impact of Immunostimulating Nutrition on the Outcome of Surgery Completed NCT00558155 Phase 4 peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven
6 Prospective Study of Celiac Block Injection: 1 vs. 2 Completed NCT00583479 Phase 4
7 Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Completed NCT00966277 Phase 4 Dalteparin
8 Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer Completed NCT01346410 Phase 4
9 Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi Completed NCT01041612 Phase 4
10 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
11 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
12 Effects of Dexmedetomidine During IRE Procedures for Solid Tumours Completed NCT02044224 Phase 4 Dexmedetomidine
13 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
14 The Importance of Albumin Infusion Rate for Plasma Volume Expansion Following Major Abdominal Surgery Completed NCT02728921 Phase 4 5% Albumin infusion 30 min;5% Albumin infusion 3 hours
15 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients Recruiting NCT02812992 Phase 4 Nab-paclitaxel;Gemcitabine
16 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
17 A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer Active, not recruiting NCT02237157 Phase 4 Gemcitabine, local delivery
18 Pre-operative Biliary SEMS RCT During Neoadjuvant Therapy Active, not recruiting NCT02238847 Phase 4
19 Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer Not yet recruiting NCT02945267 Phase 4 Nimotuzumab plus S1;Placebo plus S1
20 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Not yet recruiting NCT02570529 Phase 4 Albis®;Placebo
21 Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC Not yet recruiting NCT03257033 Phase 4 Gemcitabine;nab-paclitaxel
22 Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study Terminated NCT01768988 Phase 4 Placebo;Pregabalin
23 Quality of Life After BDA or Stents to Treat Biliary Obstruction in Pancreas Cancer Terminated NCT01887041 Phase 4
24 A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer Terminated NCT00642733 Phase 4 erlotinib [Tarceva];gemcitabine
25 A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer Unknown status NCT01586611 Phase 3 5FU, leucovorin, oxaliplatin;Gemcitabine
26 Gemcitabine or Gemcitabine and Cisplatin in the Treatment of Advanced Pancreatic Cancer Unknown status NCT00813696 Phase 3 gemcitabine;cisplatin
27 Hyperthermia European Adjuvant Trial Unknown status NCT01077427 Phase 3 Gemcitabine
28 Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III) Unknown status NCT01065870 Phase 2, Phase 3 Neoadjuvant gemcitabine, capecitabine, and docetaxel;Gemcitabine, capecitabine, docetaxel followed by radiotherapy
29 A Phase 3 Study to Compare Efficacy and Safety of Masitinib in Combination With Gemcitabine, to Placebo in Combination With Gemcitabine, in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer Unknown status NCT00789633 Phase 3 masitinib (AB1010);placebo
30 Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
31 Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer Unknown status NCT00268411 Phase 3 gemcitabine hydrochloride;oxaliplatin
32 Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine Unknown status NCT00440167 Phase 3 Gemcitabine;Capecitabine;Erlotinib
33 Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer Unknown status NCT00486460 Phase 3 Gemcitabine;Curcumin;Celebrex
34 Efficacy and Mechanisms of Acupuncture for Patients With Advanced Pancreatic Cancer Pain Unknown status NCT02510066 Phase 3
35 Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas Unknown status NCT02311439 Phase 2, Phase 3 FOLFIRINOX + CRT
36 Study of Tranexamic Acid for Reducing Blood Requirement in Patients Undergoing Major Gastro-intestinal Surgery Unknown status NCT01655641 Phase 2, Phase 3 Tranexamic acid
37 The ARTERY FIRST Approach for Resection of Pancreatic Head Cancer Unknown status NCT01332773 Phase 3
38 Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer Completed NCT00498225 Phase 3 Gemcitabine plus TS-1;TS-1;Gemcitabine
39 Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer Completed NCT01494506 Phase 3 MM-398;5 Fluorouracil;Leucovorin
40 A Phase III Study of Pancreatic Cancer Completed NCT00994721 Phase 3
41 Gemcitabine or Combination Chemotherapy Followed by Chemoradiation for Stage IB, II, or III Pancreatic Cancer Completed NCT00960284 Phase 2, Phase 3 capecitabine;cisplatin;epirubicin hydrochloride;fluorouracil;gemcitabine hydrochloride
42 Randomized Trial of EUS Neurolysis in Pancreas Cancer Completed NCT00279292 Phase 3
43 Immunotherapy Study for Surgically Resected Pancreatic Cancer Completed NCT01072981 Phase 3 Gemcitabine
44 S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer Completed NCT00075686 Phase 3 gemcitabine hydrochloride
45 Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed NCT00032175 Phase 3 capecitabine;gemcitabine hydrochloride
46 Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed NCT00425360 Phase 3 capecitabine;gemcitabine hydrochloride
47 Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer Completed NCT00005648 Phase 3 Gemcitabine with R115777;Gemcitabine with Placebo
48 Gemcitabine and Radiation Therapy Compared With Gemcitabine Alone in Treating Patients Who Have Undergone Surgery for Pancreatic Cancer Completed NCT00064207 Phase 2, Phase 3 gemcitabine hydrochloride
49 Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery Completed NCT00634725 Phase 3 capecitabine;erlotinib hydrochloride;gemcitabine hydrochloride
50 Chemotherapy With or Without Enoxaparin in Pancreatic Cancer Completed NCT00785421 Phase 2, Phase 3 enoxaparin;chemotherapy with LMWH - enoxaparin;only chemotherapy

Search NIH Clinical Center for Pancreatic Cancer 1

Genetic Tests for Pancreatic Cancer 1

Genetic tests related to Pancreatic Cancer 1:

id Genetic test Affiliating Genes
1 Pancreatic Cancer 1 29

Anatomical Context for Pancreatic Cancer 1

MalaCards organs/tissues related to Pancreatic Cancer 1:

39
Pancreas, Lung, T Cells, Liver, Colon, Testes, Breast

Publications for Pancreatic Cancer 1

Variations for Pancreatic Cancer 1

ClinVar genetic disease variations for Pancreatic Cancer 1:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 PALLD NM_001166110.1(PALLD): c.415C> T (p.Pro139Ser) single nucleotide variant risk factor rs121908291 GRCh37 Chromosome 4, 169799457: 169799457

Expression for Pancreatic Cancer 1

Search GEO for disease gene expression data for Pancreatic Cancer 1.

Pathways for Pancreatic Cancer 1

GO Terms for Pancreatic Cancer 1

Sources for Pancreatic Cancer 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....